Janus Kinase-2 V617F Mutation and Antiphospholipid Syndrome in Cerebral Sinus Venous Thrombosis: Natural History and Retrospective Bicenter Analysis.
APLA
JAK-2 mutation
sinus venous thrombosis
stroke workflow
thrombophilia
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
09
2021
accepted:
02
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Cerebral sinus venous thrombosis (CSVT) is a rare neurovascular entity, usually associated with acquired or genetic hypercoagulable states. In up to 30% of the cases it remains idiopathic. Bone marrow proliferation disorders that are associated with Janus Kinase 2 V617F mutation (JAK-2) are known causes of the systemic and cerebral thrombosis-at times despite normal blood counts-for which hematologic treatment exists. However, JAK-2 prevalence in the CSVT cases is not clear. In this retrospective analysis, data of 236 patients with CSVT admitted to two tertiary centers between 2010 and 2020 were analyzed, with emphasis on laboratory and imaging data and clinical and interventional outcomes. A total of 236 patients were included in the analysis. The patients' median age was 42 years and the average age was 44 years (±19 years), with 59% female patients. JAK-2 positivity rate was 18% (among 77 patients tested for the mutation). Patients with normal blood counts on presentation comprised 36% of the JAK-2 positive cases. Other hypercoagulability states were also investigated, with the antiphospholipid syndrome (APLA) showing the highest prevalence (11%) followed by other etiologies including oral contraceptive use, Factor V Leiden, prothrombin mutation, and malignancy. Selected JAK-2, APLA, and prothrombin mutation cases showed a more severe clinical course. JAK-2 mutation is underdiagnosed and its screening may be warranted in the cases of idiopathic CSVT, even despite normal blood counts, to allow disease-modifying treatment and blood cell count monitoring. JAK-2, APLA, and prothrombin mutation may be associated with a more complicated clinical course.
Sections du résumé
Background
UNASSIGNED
Cerebral sinus venous thrombosis (CSVT) is a rare neurovascular entity, usually associated with acquired or genetic hypercoagulable states. In up to 30% of the cases it remains idiopathic. Bone marrow proliferation disorders that are associated with Janus Kinase 2 V617F mutation (JAK-2) are known causes of the systemic and cerebral thrombosis-at times despite normal blood counts-for which hematologic treatment exists. However, JAK-2 prevalence in the CSVT cases is not clear.
Methods
UNASSIGNED
In this retrospective analysis, data of 236 patients with CSVT admitted to two tertiary centers between 2010 and 2020 were analyzed, with emphasis on laboratory and imaging data and clinical and interventional outcomes.
Results
UNASSIGNED
A total of 236 patients were included in the analysis. The patients' median age was 42 years and the average age was 44 years (±19 years), with 59% female patients. JAK-2 positivity rate was 18% (among 77 patients tested for the mutation). Patients with normal blood counts on presentation comprised 36% of the JAK-2 positive cases. Other hypercoagulability states were also investigated, with the antiphospholipid syndrome (APLA) showing the highest prevalence (11%) followed by other etiologies including oral contraceptive use, Factor V Leiden, prothrombin mutation, and malignancy. Selected JAK-2, APLA, and prothrombin mutation cases showed a more severe clinical course.
Conclusion
UNASSIGNED
JAK-2 mutation is underdiagnosed and its screening may be warranted in the cases of idiopathic CSVT, even despite normal blood counts, to allow disease-modifying treatment and blood cell count monitoring. JAK-2, APLA, and prothrombin mutation may be associated with a more complicated clinical course.
Identifiants
pubmed: 35493844
doi: 10.3389/fneur.2022.783795
pmc: PMC9046649
doi:
Types de publication
Journal Article
Langues
eng
Pagination
783795Informations de copyright
Copyright © 2022 Orion, Itsekson-Hayosh, Peretz, Mendel, Yaniv, Attia and Grizim-Merkel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Med Genet. 2007 Jun;44(6):412-6
pubmed: 17307838
Headache. 2016 Sep;56(8):1380-9
pubmed: 27350588
Br J Haematol. 2008 Nov;143(3):307-20
pubmed: 19004076
J Thromb Haemost. 2012 Jun;10(6):998-1003
pubmed: 22469236
Trends Endocrinol Metab. 2018 Jan;29(1):55-65
pubmed: 29191719
Thrombosis. 2011;2011:536062
pubmed: 22084665
Blood Cancer J. 2018 Jan 10;8(1):2
pubmed: 29321520
Blood. 2009 May 28;113(22):5617-23
pubmed: 19273837
J Thromb Haemost. 2007 Apr;5(4):708-14
pubmed: 17263783
Pharmacol Res. 2016 Sep;111:784-803
pubmed: 27473820
Thromb Haemost. 2008 Jun;99(6):1119-20
pubmed: 18521518
N Engl J Med. 1998 Jun 18;338(25):1793-7
pubmed: 9632445
Blood. 2013 Nov 28;122(23):3705-6
pubmed: 24288407
Stroke. 2005 Sep;36(9):1927-32
pubmed: 16100024
Blood. 2014 Mar 6;123(10):1544-51
pubmed: 24366362
Curr Neurol Neurosci Rep. 2014 Nov;14(11):496
pubmed: 25217248
Circulation. 2014 Aug 19;130(8):e68-70
pubmed: 25135131
Int J Stroke. 2009 Apr;4(2):111-23
pubmed: 19383052
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Am J Hematol. 2019 Jan;94(1):133-143
pubmed: 30281843
Stroke. 2011 Apr;42(4):1158-92
pubmed: 21293023
Stroke. 2004 Mar;35(3):664-70
pubmed: 14976332
Stroke. 2009 Jul;40(7):2356-61
pubmed: 19478226
Thromb Res. 2009 Sep;124(4):409-17
pubmed: 19299003
Am J Hematol. 2011 Aug;86(8):668-76
pubmed: 21674578
Cancer. 2006 Nov 1;107(9):2206-11
pubmed: 16998940
Am J Hematol. 2015 Feb;90(2):162-73
pubmed: 25611051
JAMA Oncol. 2015 Apr;1(1):97-105
pubmed: 26182311
Leukemia. 2010 Sep;24(9):1574-9
pubmed: 20631743
Am J Hematol. 2020 Dec;95(12):1599-1613
pubmed: 32974939
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187